RESUMEN
Clostridioides difficile infection (CDI) is a toxin-mediated infection in the gut and a major burden on healthcare facilities worldwide. We rationalized that it would be beneficial to design an antibody therapy that is delivered to, and is active at the site of toxin production, rather than neutralizing the circulating and luminal toxins after significant damage of the layers of the intestines has occurred. Here we describe a highly potent therapeutic, OraCAb, with high antibody titers and a formulation that protects the antibodies from digestion/inactivation in the gastrointestinal tract. The potential of OraCAb to prevent CDI in an in vivo hamster model and an in vitro human colon model was assessed. In the hamster model we optimized the ratio of the antibodies against each of the toxins produced by C. difficile (Toxins A and B). The concentration of immunoglobulins that is effective in a hamster model of CDI was determined. A highly significant difference in animal survival for those given an optimized OraCAb formulation versus an untreated control group was observed. This is the first study testing the effect of oral antibodies for treatment of CDI in an in vitro gut model seeded with a human fecal inoculum. Treatment with OraCAb successfully neutralized toxin production and did not interfere with the colonic microbiota in this model. Also, treatment with a combination of vancomycin and OraCAb prevented simulated CDI recurrence, unlike vancomycin therapy alone. These data demonstrate the efficacy of OraCAb formulation for the treatment of CDI in pre-clinical models.
Asunto(s)
Daño del ADN , Reparación del ADN , Replicación del ADN , ADN/genética , Neoplasias/genética , Antineoplásicos/farmacología , ADN/efectos de los fármacos , ADN/metabolismo , Humanos , Modelos Genéticos , Simulación de Dinámica Molecular , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismoAsunto(s)
Chaperonas Moleculares/metabolismo , Neoplasias/metabolismo , Amiloidosis/tratamiento farmacológico , Amiloidosis/metabolismo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Humanos , Enfermedades Metabólicas/tratamiento farmacológico , Enfermedades Metabólicas/metabolismo , Chaperonas Moleculares/química , Neoplasias/tratamiento farmacológico , Enfermedades Neurodegenerativas/tratamiento farmacológico , Enfermedades Neurodegenerativas/metabolismo , Enfermedades de la Retina/tratamiento farmacológico , Enfermedades de la Retina/metabolismoAsunto(s)
Neoplasias/tratamiento farmacológico , Enfermedades del Sistema Nervioso/tratamiento farmacológico , Proteínas/antagonistas & inhibidores , Humanos , Neoplasias/química , Neoplasias/metabolismo , Enfermedades del Sistema Nervioso/metabolismo , Unión Proteica/efectos de los fármacos , Mapas de Interacción de Proteínas , Proteínas/química , Proteínas/metabolismoAsunto(s)
Proteínas/química , Proteínas/metabolismo , ADN/química , ADN/metabolismo , Enfermedad , Humanos , Lípidos/química , Unión Proteica , ARN/química , ARN/metabolismoAsunto(s)
Inflamación/complicaciones , Inflamación/inmunología , Estrés Fisiológico , Animales , Epilepsia/etiología , Epilepsia/inmunología , Cardiopatías/etiología , Cardiopatías/inmunología , Humanos , Inflamasomas/inmunología , Trastornos del Humor/etiología , Trastornos del Humor/inmunología , Neoplasias/etiología , Neoplasias/inmunología , Enfermedades Neurodegenerativas/etiología , Enfermedades Neurodegenerativas/inmunología , Estrés Oxidativo , Investigación Biomédica TraslacionalRESUMEN
The number of people around the world suffering from depression has dramatically increased in last few decades. It has been predicted that by 2020 depression will become the second most common cause of disability. Furthermore, depression is often misdiagnosed and confused with other psychiatric disorders showing similar symptoms, i.e., anxiety and bipolar disorder, due to the fact that diagnosing is often carried out by medical workers who are not psychiatrically trained. These facts prompt us to prepare this review which focuses on alterations in gene expression in depression. We believe that an in-depth knowledge of molecular bases of behavior in depression and other mood disorders would be of a great benefit for the correct diagnosing of these disorders, as well as for prescribing a treatment that best suits each individual depending on expression alterations in depression-related genes. Therefore, the main aim of this review is to promote further translational research on the biochemistry of mood disorders and take the results further for the design of new targeted therapeutics that can be used for personalized treatment with minimal adverse effects.
Asunto(s)
Ansiedad/diagnóstico , Depresión/genética , Regulación de la Expresión Génica/genética , Biosíntesis de Proteínas/genética , Antidepresivos/química , Antidepresivos/uso terapéutico , Ansiedad/genética , Ansiedad/patología , Ansiedad/terapia , Ritmo Circadiano/genética , Depresión/diagnóstico , Depresión/patología , Depresión/terapia , Humanos , Terapia Molecular Dirigida , Neurotransmisores/biosíntesis , Neurotransmisores/genética , Medicina de Precisión , Transducción de Señal , Sinapsis/genéticaRESUMEN
Schizophrenia is a severe mental illness with a biological basis. However, the search for reliable biomarkers suitable for clinical routine has been futile so far. Accordingly, there is a need for innovative approaches such as genomics and proteomics to achieve this goal. In the present study, we compared metabolomic and proteomic data from 26 schizophrenia patients as well as from unaffected controls carefully matched for age and gender in a multi-platform approach. The combined analysis identified many signatures with initially good biomarker characteristics. After statistical analysis and comparison of these identified serum metabolites (analysed by Gas Chromatography Mass Spectrometry) and hydrophobic serum proteins (analysed by matrix-assisted laser desorption ionisation mass spectrometry), several markers (e.g., 2-piperidinec carboxylic acid, 6-deoxy-mannofuranose, galactoseoxime and a serum peptide of m/z 3177) were determined as having the best discriminating value between the groups. Our findings represent a proof of principle indicating that metabolomic and proteomic approaches can be successfully used in psychiatric biomarker research, even though the results should be regarded as preliminary with a need for replication in larger samples.
Asunto(s)
Proteínas Sanguíneas/metabolismo , Metaboloma/fisiología , Proteoma/metabolismo , Esquizofrenia/sangre , Adulto , Anciano , Estudios de Casos y Controles , Estudios de Cohortes , Femenino , Humanos , Lípidos/sangre , Masculino , Persona de Mediana Edad , Proteómica/métodos , Curva ROC , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Adulto JovenRESUMEN
Anaplastic Lymphoma Kinase (ALK) plays a major role in developing tumor processes and therefore has emerged as a validated therapeutic target. Applying atomistic molecular dynamics simulations on the wild type enzyme and the nine most frequently occurring and clinically important activation mutants we revealed important conformational effects on key interactions responsible for the activation of the enzyme.